Epigenetic Heterogeneity in HIV-1 Latency Establishment

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Matsuda, Yuka ^a   Kobayashi Ishihara, Mie ^b   Fujikawa, Dai ^a   Ishida, Takaomi ^c   Watanabe, Toshiki ^a   Yamagishi, Makoto ^a  

^a Graduate School of Frontier Sciences   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; POLYCOMB REPRESSIVE COMPLEX 2; SMALL INTERFERING RNA;

ANTAGONISTS AND INHIBITORS; CHROMATIN IMMUNOPRECIPITATION; GENETIC EPIGENESIS; GENETICS; HEK293 CELL LINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; JURKAT CELL LINE; METABOLISM; METHYLATION; PHYSIOLOGY; REPORTER GENE; RNA INTERFERENCE; VIRUS LATENCY;

CHROMATIN IMMUNOPRECIPITATION; EPIGENESIS, GENETIC; GENES, REPORTER; HEK293 CELLS; HISTONES; HIV-1; HUMANS; JURKAT CELLS; METHYLATION; POLYCOMB REPRESSIVE COMPLEX 2; RNA INTERFERENCE; RNA, SMALL INTERFERING; VIRUS LATENCY;

EID: 84938059016     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07701     Document Type: Article

References (59)

1. Perelson, A. S. et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387, 188-191 (1997).
2. Gulick, R. M. et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337, 734-739 (1997).
3. Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295-1300 (1997).
4. Wong, J. K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291-1295 (1997).
5. Chun, T. W.,Davey, R. T., Jr, Engel, D., Lane, H. C.& Fauci, A. S. Re-emergence of HIV after stopping therapy. Nature 401, 874-875 (1999).
6. Chun, T. W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U.S.A. 94, 13193-13197 (1997).
7. Bailey, J. R. et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD41 T cells. J. Virol. 80, 6441-6457 (2006).
8. Kieffer, T. L. et al. (2004) Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J. Infect. Dis. 189, 1452-1465 (2004).
9. Frenkel, L. M. et al. Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy. J. Virol. 77, 5721-5730 (2003).
10. Kinoshita, S., Chen, B. K., Kaneshima, H., Nolan, G. P. Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells. Cell 95, 595-604 (1998).
11. Perkins, N. D. et al. A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation. EMBO J. 12, 3551-3558 (1993).
12. Kim, Y. K., Mbonye, U., Hokello, J., Karn, J. T-cell receptor signaling enhances transcriptional elongation from latent HIV proviruses by activating P-TEFb through an ERK-dependent pathway. J. Mol. Biol. 410, 896-916 (2011).
13. Kao, S. Y., Calman, A. F., Luciw, P. A., Peterlin, B. M. Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature 330, 489-493 (1987).
14. Wei, P., Garber, M. E., Fang, S. M., Fischer, W. H., Jones, K. A. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its highaffinity, loop-specific binding to TAR RNA. Cell 92, 451-462 (1998).
15. Van Lint, C., Emiliani, S., Ott, M., Verdin, E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J. 15, 1112-1120 (1996).
16. Williams, S. A. et al. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J. 25, 139-149 (2006).
17. Tyagi, M., Karn, J. CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J. 26, 4985-4995 (2007).
18. Jiang, G., Espeseth, A., Hazuda, D. J.,Margolis, D. M. c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J. Virol. 81, 10914-10923 (2007).
19. Cohen, J. Exploring how to get at-and eradicate-hidden HIV. Science 279, 1854-1855 (1998).
20. Chun, T. W., Engel, D.,Mizell, S. B., Ehler, L. A., Fauci, A. S. Induction of HIV-1 replication in latently infected CD41 T cells using a combination of cytokines. J. Exp. Med. 188, 83-91 (1998).
21. Chun, T. W. et al. Effect of interleukin-2 on the pool of latently infected, resting CD41 T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat. Med. 5, 651-655 (1999).
22. Davey, R. T., Jr. et al.HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. U.S.A. 96, 15109-15114 (1999).
23. Stellbrink, H. J. et al. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS 16, 1479-1487 (2002).
24. Lafeuillade, A. et al. Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission. J. Acquir. Immune Defic. Syndr. 26, 44-55 (2001).
25. Lehrman, G. et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366, 549-555 (2005).
26. Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482-485 (2012).
27. Ruelas, D. S., Greene, W. C. An integrated overview of HIV-1 latency. Cell 155, 519-529 (2013).
28. Chun, T. W. et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183-188 (1997).
29. Ylisastigui, L., Archin, N. M., Lehrman, G., Bosch, R. J.,Margolis, D. M. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 18, 1101-1108 (2004).
30. Ishida, T., Hamano, A., Koiwa, T.,Watanabe, T. 59 long terminal repeat (LTR)-selective methylation of latently infected HIV-1 provirus that is demethylated by reactivation signals. Retrovirology 3, 69 (2006).
31. Blazkova, J. et al. CpG methylation controls reactivation of HIV from latency. PLoS Pathog. 5, e1000554 (2009).
32. Schroder, A. R. et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110, 521-529 (2002).
33. Han, Y. et al. Resting CD41 T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J. Virol. 78, 6122-6133 (2004).
34. McCabe, M. T. et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108-112 (2012).
35. Emiliani, S. et al. Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line. J. Virol. 72, 1666-1670 (1998).
36. Colin, L., Van Lint, C. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 6, 111 (2009).
37. Archin, N. M. et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retroviruses. 25, 207-212 (2009).
38. Friedman, J. et al. Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. J. Virol. 85, 9078-9089 (2011).
39. Kouzarides, T. Chromatin modifications and their function. Cell 128, 693-705 (2007).
40. Barski, A. et al. High-resolution profiling of histone methylations in the human genome. Cell 129, 823-837 (2007).
41. Geeraert, L., Kraus, G., Pomerantz, R. J. Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu. Rev. Med. 59, 487-501 (2008).
42. du Chene, I. et al. Suv39H1 and HP1gamma are responsible for chromatinmediated HIV-1 transcriptional silencing and post-integration latency. EMBO J. 26, 424-435 (2007).
43. Marban, C. et al. Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J. 26, 412-423 (2007).
44. Duverger, A. et al. Determinants of the establishment of human immunodeficiency virus type 1 latency. J. Virol. 83, 3078-3093 (2009).
45. Burnett, J. C.,Miller-Jensen, K., Shah, P. S., Arkin, A. P., Schaffer, D. V. Control of stochastic gene expression by host factors at the HIV promoter. PLoS Pathog. 5, e1000260 (2009).
46. Duverger, A. et al. An AP-1 binding site in the enhancer/core element of the HIV-1 promoter controls the ability of HIV-1 to establish latent infection. J. Virol. 87, 2264-2277 (2013).
47. Tyagi, M., Pearson, R. J., Karn, J. Establishment of HIV latency in primary CD41 cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J. Virol. 84, 6425-6437 (2010).
48. Budhiraja, S., Famiglietti, M., Bosque, A., Planelles, V., Rice, A. P. Cyclin T1 and CDK9 T-loop phosphorylation are downregulated during establishment of HIV-1 latency in primary resting memory CD41 T cells. J. Virol. 87, 1211-1220 (2013).
49. Ho, Y. C. et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155, 540-551 (2013).
50. Kirmizis, A. et al. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev. 18, 1592-1605 (2004).
51. Yamagishi, M. et al. Polycomb-mediated loss of miR-31 activates NIK-dependent NF-kappaB pathway in adult T cell leukemia and other cancers. Cancer Cell 21, 121-135 (2012).
52. Weinberger, L. S., Burnett, J. C., Toettcher, J. E., Arkin, A. P., Schaffer, D. V. Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell 122, 169-182 (2005).
53. Baldauf,H.M. et al. SAMHD1restricts HIV-1 infection in resting CD4(1) T cells. Nat. Med. 18, 1682-1687 (2012).
54. Pan, X., Baldauf, H. M., Keppler, O. T., Fackler, O. T. Restrictions to HIV-1 replication in resting CD41 T lymphocytes. Cell Res. 23, 876-885 (2013).
55. Miyoshi, H., Takahashi, M., Gage, F. H., Verma, I. M. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc. Natl. Acad. Sci. U.S.A. 94, 10319-10323 (1997).
56. O'Doherty, U., Swiggard, W. J., Malim, M. H. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J. Virol. 74, 10074-10080 (2000).
57. Fukumori, T. et al. Regulation of cell cycle and apoptosis by human immunodeficiency virus type 1 Vpr. Microbes Infect. 2, 1011-1017 (2000).
58. Yamagishi, M. et al. Retroviral delivery of promoter-targeted shRNA induces long-term silencing of HIV-1 transcription. Microbes Infect. 11, 500-508 (2009).
59. Brussel, A., Sonigo, P. Analysis of early human immunodeficiency virus type 1 DNA synthesis by use of a new sensitive assay for quantifying integrated provirus. J. Virol. 77, 10119-10124 (2003).